Ana Carolina Apolônio

Ana Carolina Apolônio

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Industrial Crops and Products
Verified
Journal Article
Closed access
NPNícolas de C.C. Pinto
Nícolas de C.C. Pinto
LCLara M. Campos
Lara M. Campos
AEAnna Carolina S. Evangelista
Anna Carolina S. Evangelista
ALAri S.O. Lemos
Ari S.O. Lemos
Thiago P. SilvaThiago P. Silva
Thiago P. Silva
RFRodrigo L. Fabri
Rodrigo L. Fabri

21 September 2023 in Polymers
Verified
Journal Article
Open access
PDF file
Thiago Medeiros ZacaronThiago Medeiros Zacaron
Thiago Medeiros Zacaron
MSMariana Leite Simões e Silva
Mariana Leite Simões e Silva
MCMirsiane Pascoal Costa
Mirsiane Pascoal Costa
DSDominique Mesquita e Silva
Dominique Mesquita e Silva
ASAllana Carvalho Silva
Allana Carvalho Silva
GTGuilherme Diniz Tavares
Guilherme Diniz Tavares
The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes of death worldwide. In this sense, in addition to the high prevalence of diseases such as asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging respiratory diseases, particularly those caused by members of the coronavirus family, have contributed to a significant number of deaths on a global scale over the last two decades. Therefore, several studies have been conducted to optimize the efficacy of treatments against these diseases, focusing on pulmonary drug delivery using nanomedicine. Thus, the development of nanocarriers has emerged as a promising alternative to overcome the limitations of conventional therapy, by increasing drug bioavailability at the target site and reducing unwanted side effects. In this context, nanoparticles composed of chitosan (CS) show advantages over other nanocarriers because chitosan possesses intrinsic biological properties, such as anti-inflammatory, antimicrobial, and mucoadhesive capacity. Moreover, CS nanoparticles have the potential to enhance drug stability, prolong the duration of action, improve drug targeting, control drug release, optimize dissolution of poorly soluble drugs, and increase cell membrane permeability of hydrophobic drugs. These properties could optimize the performance of the drug after its pulmonary administration. Therefore, this review aims to discuss the potential of chitosan nanoparticles for pulmonary drug delivery, highlighting how their biological properties can improve the treatment of pulmonary diseases, including their synergistic action with the encapsulated drug.

13 April 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
ALAri S. O. Lemos
Ari S. O. Lemos
LCLara M. Campos
Lara M. Campos
LMLívia Melo
Lívia Melo
MGMaria C. M. R. Guedes
Maria C. M. R. Guedes
LOLuiz G. Oliveira
Luiz G. Oliveira
RFRodrigo Luiz Fabri
Rodrigo Luiz Fabri
Psychorubrin, a natural pyranonaphthoquinone found in different plants, has become an interesting compound in the search for new antimicrobial therapeutic agents. Here, we investigated the potential antagonistic activity of psychorubrin against planktonic and biofilm bacteria. First, psychorubrin was tested against several Gram-positive and Gram-negative bacteria strains by a broth microdilution susceptibility method. Second, bacterial killing assay, bacterial abundance, and membrane viability were evaluated. The nucleotide leakage assay was used to verify membrane destabilization while antibiofilm activities were analyzed by the effect on established biofilm, static biofilm formation, isolation of biofilm matrix assay and scanning electron microscopy. In parallel, the combinatorial effect of psychorubrin and chloramphenicol was evaluated by the checkerboard method. Psychorubrin was active against Gram-positive bacteria, showing rapid time-dependent kinetics of bacterial killing, amplified nucleotide leakage, and greater activity against the methicillin-resistant species (MRSA) Staphylococcus aureus 33591 and 33592 and Staphylococcus pyogenes 10096. Psychorubrin also interfered with the composition of the biofilm matrix by reducing the total content of carbohydrates and proteins. A synergic effect between psychorubrin and chloramphenicol was observed for S. aureus 33592 and S. pyogenes 10096 while an additive effect was detected for S. aureus 33591. Our findings demonstrate, for the first time, an antagonistic activity of psychorubrin against bacteria not only in their planktonic forms but also in biofilms, and identify bacterial membranes as primary targets for this compound. Based on these observations, psychorubrin has a good potential for the design of novel antimicrobial agents.

1 May 2010 in Research in Microbiology
Verified
Journal Article
Closed access
KSKênia Valéria dos Santos
Kênia Valéria dos Santos
CDCláudio Galuppo Diniz
Cláudio Galuppo Diniz
LVLuciano de Castro Veloso
Luciano de Castro Veloso
HAHélida Monteiro de Andrade
Hélida Monteiro de Andrade
MGMario da Silva Giusta
Mario da Silva Giusta
LFLuiz de Macêdo Farias
Luiz de Macêdo Farias

1 November 2018 in Industrial Crops and Products
Verified
Journal Article
Closed access
LCLara M. Campos
Lara M. Campos
LMLívia de Melo
Lívia de Melo
ALAri S.O. Lemos
Ari S.O. Lemos
MGMaria Clara M.R. Guedes
Maria Clara M.R. Guedes
Thiago P. SilvaThiago P. Silva
Thiago P. Silva
RFRodrigo Luiz Fabri
Rodrigo Luiz Fabri

24 January 2010 in APMIS
Verified
Journal Article
Closed access
PDF file
MSMireille Ângela Bernardes Sousa
Mireille Ângela Bernardes Sousa
EMEdilberto Nogueira Mendes
Edilberto Nogueira Mendes
AAAna Carolina Apolônio
Ana Carolina Apolônio
LFLuiz DE Macêdo Farias
Luiz DE Macêdo Farias
PMPaula Prazeres Magalhães
Paula Prazeres Magalhães